Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Zoledronic acid Stories

2011-08-30 09:22:00

NEW YORK, Aug. 30, 2011 /PRNewswire/ -- The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, notes with commingled optimism and circumspection a new report that some troubled drugs, including Fosamax, might aid in the treatment of certain cancers. According to a recent Reuters report, a new study "adds to evidence that bone drugs may play a role in suppressing cancer development, although there is still no proof that taking the...

2011-08-22 08:02:00

THOUSAND OAKS, Calif., Aug. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Bone is one of the most common places for...

2011-07-28 07:32:00

NEW YORK, July 28, 2011 /PRNewswire/ -- A study published by ITG this week revealed that U.S. oncologists expect Amgen's (NASDAQ: AMGN) recently approved XGEVA (denosumab) to become the top-prescribed drug over the next year for the prevention of skeletal-related events (SREs) in prostate cancer patients. Furthermore, although Novartis' (NYSE: NVS) Zometa (zoledronic acid) will likely remain the top-prescribed drug for preventing SREs in breast and lung cancer patients, physicians in the...

2011-07-26 00:00:30

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is eagerly awaiting the report of an FDA panel being convened in September to discuss Fosamax, and specifically whether the drug increases incidence of throat cancer. New York, NY (PRWEB) July 25, 2011 According to an article published by Bloomberg on July 21, in advance of an advisory panel meeting on September 9 to discuss the long-term safety of drugs used to treat...

2011-07-15 06:01:00

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA...

2011-06-27 15:37:00

THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone. The...

2011-06-07 00:00:32

The Rottenstein Law Group, which represents clients with claims stemming from the rare severe side effects of the drug Fosamax, urges those who have taken Fosamax to consult doctors to determine whether they are at risk for femur fractures, even in light of recent suggestions that the risks to patients are less than previously thought. New York, NY (PRWEB) June 06, 2011 According to a post on the Web site of the American Council on Science and Health on June 1: "A new study should allay the...

2011-06-06 20:02:00

A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. The new research findings will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston. "Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease fracture risk," said Andrew...

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-20 06:30:00

THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. If approved by the...